Navigation Links
Iomai to Announce Third Quarter 2007 Financial Results and Host Webcast on Tuesday, November 13

GAITHERSBURG, Md., Nov. 9 /PRNewswire-FirstCall/ -- Iomai Corporation (Nasdaq: IOMI) today announced that it will release third quarter 2007 financial results before the markets open and hold a conference call and live webcast to discuss corporate and clinical progress on Tuesday, Nov. 13, 2007 at 11 a.m. Eastern Time.

Conference Call Details

To access the live conference call on Tuesday, Nov. 13 at 11 a.m. Eastern Time via phone, please dial 866-510-0707 from the United States and Canada or 617-597-5376 internationally. The conference ID is 85613352. Please dial in approximately 10 minutes prior to the start of the call. A telephone replay will be available beginning approximately one hour after the call through Nov. 20 and may be accessed by dialing 888-286-8010 from the United States and Canada or 617-801-6888 internationally. The replay passcode is 49212414.

To access the live and subsequently archived webcast of the conference call, go to the Investor Relations section of the Company's website at . Please connect to the web site at least 15 minutes prior to the call to allow for any software download that may be necessary. The webcast is also being distributed through the Thomson StreetEvents Network. Individual investors can listen to the call at, Thomson's individual investor portal, powered by StreetEvents. Institutional investors can access the call via Thomson StreetEvents (, a password-protected event management site.

About Iomai Corporation

Iomai Corporation discovers and develops vaccines and immune system stimulants, delivered via a novel, needle-free technology called transcutaneous immunization (TCI). TCI taps into the unique benefits of a major group of antigen-presenting cells found in the outer layers of the skin (Langerhans cells) to generate an enhanced immune response. Iomai is leveraging TCI to enhance the efficacy of existing vaccines, develop new vaccines that are viable only through transcutaneous administration and expand the global vaccine market. Iomai currently has four product candidates in development: three targeting influenza and pandemic flu and one to prevent travelers' diarrhea. For more information on Iomai, please visit

SOURCE Iomai Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Iomai CEO to Speak at Natixis Bleichroeder Hidden Gems Conference on Monday
2. Iomai Chief Scientific Officer Dr. Gregory Glenn Details Development of Travelers Diarrhea Patch at Keystone Conference
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
6. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
7. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
8. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
9. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
10. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
11. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
Post Your Comments:
(Date:11/24/2015)... -- --> --> ... Market by Product & Services (Primer, Probe, Custom Oligos, ... End-User (Research, Pharmaceutical & Biotech, Diagnostic Labs) - Global ... expected to reach USD 1,918.6 Million by 2020 from ... 10.1% during the forecast period. Browse 183 ...
(Date:11/24/2015)...  Tikcro Technologies Ltd. (OTCQB: TIKRF) today announced that its Annual General ... a.m. Israel time, at the law offices of ... 36 th Floor, Tel Aviv, Israel . ... Izhak Tamir to the Board of Directors; , election ... , approval of an amendment to certain terms of options granted to ...
(Date:11/24/2015)... ... November 24, 2015 , ... Creation Technologies ... being named to Deloitte's 2015 Technology Fast 500 list of the fastest growing ... a FDA-cleared, Class II medical device that speeds up orthodontic tooth movement by ...
(Date:11/24/2015)... MUNICH and NEW YORK , ... irst investment by Bristol-Myers Squibb in a ... Bristol-Myers Squibb Company in which the companies ... products in immuno-oncology and other areas of unmet medical need. ... Squibb in LSP 5, the latest LSP fund. This is ...
Breaking Biology Technology:
(Date:11/9/2015)... , Nov. 9, 2015  Synaptics Inc. (NASDAQ: ... today announced broader entry into the automotive market with ... match the pace of consumer electronics human interface innovation. ... are ideal for the automotive industry and will be ... Europe , Japan ...
(Date:10/29/2015)... Daon, a global leader in mobile biometric ... new version of its IdentityX Platform , IdentityX ... have already installed IdentityX v4.0 and are ... FIDO UAF certified server component as an option ... features. These customers include some of the largest and ...
(Date:10/27/2015)... , Oct. 27, 2015 In the present ... of concern for various industry verticals such as banking, ... to the growing demand for secure & simplified access ... ,sectors, such as hacking of bank accounts, misuse of ... equipment such as PC,s, laptops, and smartphones are expected ...
Breaking Biology News(10 mins):